Skip to main content
Clinical Trials/CTRI/2019/05/018966
CTRI/2019/05/018966Not yet recruitingPhase 2

A Double Blind Randomised Controlled trial comparing Lactulose plus Rifaximin with Lactulose plus Rifaximin plus L-Ornithine L- Aspartate in treatment of Overt Hepatic Encephalopathy(Grade III-Grade IV) in patients with cirrhosis

Department of Gastroenterology G B Pant Hospital0 sites0 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
Phase 2
Status
Not yet recruiting
Sponsor

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • 1. Age of patients 18-70 years.
  • 2. Hepatic cirrhosis based on clinical, biochemical, radiological and/or histological data
  • 3. Patients with overt acute grade 3 and 4 HE, according to the West Haven criteria, with or without precipitating factors

Exclusion Criteria

  • 1.Acute on chronic liver failure
  • 2.Hepatocellular carcinoma
  • 3.Wilsonâ??s disease
  • 4.Advanced cardiac or pulmonary disease
  • 5.Neurologic disease (including head injury and drug intoxication) CNS active drugs.
  • 6.Pregnancy or breast feeding
  • 7.Cirrhotics with h/o HE already taking L-Ornithine â?? L â??Aspartate
  • 8.Presence of underlying chronic renal failure (serum creatinine > 1.5mg/dl)
  • 9.Psychiatric illness; patients who are on sedatives and antidepressants
  • 10.Those who do not give informed consent

Investigators

Sponsor
Department of Gastroenterology G B Pant Hospital

Similar Trials